Myeloid leukaemia in children with Down syndrome: report of the registry-based French experience between 1990 and 2003
| Autor: | Jacqueline Clavel, André Baruchel, Fabienne Nacka, Julie Tandonnet, Yves Perel |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Down syndrome Pediatrics medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents Disease-Free Survival Blood cancer Epidemiology medicine Humans Registries Chemotherapy Dose-Response Relationship Drug business.industry Cytarabine Infant Hematology medicine.disease Transplantation Regimen Treatment Outcome Oncology Leukemia Myeloid Child Preschool Pediatrics Perinatology and Child Health Female France Myeloid leukaemia Down Syndrome business medicine.drug |
| Zdroj: | Pediatric bloodcancer. 54(7) |
| ISSN: | 1545-5017 |
| Popis: | Aim To determine the epidemiology of myeloid leukaemia (ML) in children with Down syndrome (DS) and the efficacy of two approaches, low-dose cytarabine-based regimen (LDC) and standard-dose intensive chemotherapy (SD). Procedure All children with Down syndrome aged from 2 months to 15 years with ML/myelodysplasia registered in the French registry between January 1990 and December 2003 were included. Results Forty-four patients were included. The median age was 1.75 years. The French–America–British subtypes were as follows: M7: 24, M0: 6, M2: 5, M6: 2. Forty-three patients were treated with curative prospect, 20 patients with LDC regimen and 22 according to SD protocols, 1 was given the LDC regimen plus autologous stem-cell transplantation. The event-free survival (EFS) and overall survival (OS) at 5 years were 64.4% and 76.8%. At 5 years, OS in LDC and SD groups were 65% and 85.9% (P = 0.08). EFS were 45% and 80.3% respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text